Davies MJ, et al. - In this post hoc analysis, clinicians evaluated the impacts of canagliflozin on the components of metabolic syndrome in patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome. The data showed that canagliflozin was correlated with improvements in all components of metabolic syndrome in patients with T2DM and metabolic syndrome, whereas glimepiride and sitagliptin only improved glycemic components over 52 weeks.

Methods

• This observations was based on data from 2 head-to-head studies of canagliflozin in patients with T2DM on background metformin versus glimepiride (study 1) and background metformin plus sulfonylurea versus sitagliptin 100 mg (study 2).
• They investigated alterations from baseline in glycemic efficacy, anthropometric measures, BP, and lipids with canagliflozin versus glimepiride and sitagliptin at week 52 in patients who met ≥2 of the criteria for metabolic syndrome (in addition to T2DM): triglycerides ≥1.7 mmol/L; high-density lipoprotein cholesterol (HDL-C) <1.0 mmol/L (men) or <1.3 mmol/L (women); waist circumference ?102 cm (non-Asian men), ≥88 cm (non-Asian women), >90 cm (Asian men), or >80 cm (Asian women); diagnosis of hypertension or meeting BP-related criteria (systolic BP ≥130 mmHg or diastolic BP≥85 mmHg).
• They analyzed safety based on adverse event reports.

Results

• They observed that canagliflozin 100 and 300 mg provided similar and greater HbA1c reductions versus glimepiride, respectively in study 1.
• In study 2, it was demonstrated that canagliflozin 300 mg served greater HbA1c lowering versus sitagliptin 100 mg.
• The obtained data Indicate that canagliflozin also reduced fasting plasma glucose, body weight, body mass index, waist circumference, BP, and triglycerides, and increased HDL-C and low-density lipoprotein cholesterol versus glimepiride and sitagliptin. Canagliflozin was generally well tolerated in each study.